Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

Last updated: May 27, 2021
Sponsor: Linmarie Sikich
Overall Status: Completed

Phase

2

Condition

Autism

Williams Syndrome

Asperger's Disorder

Treatment

N/A

Clinical Study ID

NCT01944046
Pro00063950
1U01HD073984
13-0593
  • Ages 3-17
  • All Genders

Study Summary

The purpose of this research study is to learn about the effects of supplemental intranasal oxytocin as a treatment for improving social difficulties in children and adolescents with autism. This study will also provide additional information about the safety and tolerability of intranasal oxytocin. Investigators expect oxytocin will increase social motivation, improving daily living skills and quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Be between the ages of 3 years 0 months and 17 years 11 months at the time ofrandomization
  • Be diagnosed by clinician experienced in assessment of ASD with autistic disorder,Asperger's syndrome, or PDD-NOS using DSM-V-TR criteria
  • Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic ObservationScale (ADOS, Lord et al., 2001)
  • Must have clinical diagnosis of ASD confirmed using the Autism DiagnosticInterview-Revised (ADI-R, Rutter, 2003). ASD criteria proposed by Risi (2006).Specifically, subject must be within 1 point of autism criteria on both social andcommunication domains of the ADI or meet autism criteria in one of these ADI domainsand come within 2 points of autism criteria in the other
  • Have a guardian who is able to provide informed consent
  • If cognitively able, subject must be able to provide informed assent/consent

Exclusion

Exclusion Criteria:

  • Have a known diagnosis of Rett Syndrome or Childhood Disintegrative Disorder, or havemarked sensory impairment such as deafness or blindness
  • Have active cardiovascular disease or renal disease that is not controlled bymedication
  • Subjects who are pregnant, lactating, or who refuse to practice contraception ifsexually active
  • Subjects who have had changes in allied health therapies, behavioral or educationalinterventions within the two months prior to randomization other than those associatedwith school holidays
  • Subjects who have had changes in psychiatric medications within 4 weeks ofrandomization
  • Subjects who have had previous chronic treatment with oxytocin
  • Subjects who have caretakers who are unable to speak English, be consistently presentat visits to report on symptoms, or are otherwise judged as unable to comply with theprotocol by the data collection site team
  • Subjects with active seizures within the 6 months preceding screening or baseline -added part way through study in response to subject death.

Study Design

Total Participants: 290
Study Start date:
August 01, 2014
Estimated Completion Date:
November 30, 2017

Study Description

There is a tremendous unmet need for accessible treatments that address core symptoms of ASD and are safe for sustained use. The Study of Oxytocin in ASD to improve Reciprocal Social Behaviors or (SOARS-B) will test a very promising potential treatment-intranasal oxytocin-for ASD's fundamental social communication deficits in a large, group of verbal and nonverbal children. SOARS-B will also provide information about the regulation of DNA methylation and transcription of the oxytocin receptor gene (OXTR), as well as other genes relevant to oxytocin's CNS activity, as a function of time and in response to oxytocin treatment. These data will fill a key gap in our understanding of oxytocin's role in ASD and its ability to alter epigenetic modifications of the OXTR.

Connect with a study center

  • Lurie Center for Autism, Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Mount Sinai School of Medicine

    New York, New York 10029
    United States

    Site Not Available

  • Center for Autism and the Developing Brain

    White Plains, New York 10605
    United States

    Site Not Available

  • The University of North Carolina at Chapel Hill, Department of Psychiatry

    Chapel Hill, North Carolina 27517
    United States

    Site Not Available

  • Duke Center for Autism and Brain Development

    Durham, North Carolina 27705
    United States

    Site Not Available

  • Duke University , Genetics Center

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Vanderbilt University

    Nashville, Tennessee 37212
    United States

    Site Not Available

  • Seattle Children's Hospital Research Institute

    Seattle, Washington 98105
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.